Sandra Cantilena

Sandra Cantilena has over 13 years of experience in the scientific field. Sandra began their career in 2007 as a Research Technician at Imperial College London. In 2008, they moved to the Institute of Child Health, University College London, where they worked as a Research Assistant. In this role, they managed a research project to identify new surface markers in Neuroblastoma, designed experimental protocols, gathered published scientific data and interpreted data. In 2013, they joined UCL as a Postdoctoral Research Associate and a Research Assistant and PhD student part-time. During this time, they led a research project to identify FDA approved drugs degrading MLL-fusion proteins in Acute Myeloid Leukaemia (AML) using molecular and cellular biology techniques. Sandra also worked as a Research Technician at UCL Cancer Institute, where they focused on basic research on immune-regulation and cancer immunology. Most recently, in 2022, they joined Hemispherian AS as a Molecular Biology Scientist.

Sandra Cantilena has an extensive education history. Sandra obtained their Doctor of Philosophy, Ph.D. in Oncology and Cancer Biology from UCL in 2018. In 2005, they completed a Master Degree in Clinical Cytometric Diagnostics from Università degli Studi di Urbino Carlo Bo. Sandra also holds a Bachelors in Biological Science from Universita' degli Studi di Napoli Federico II, which they obtained in Biochemistry and Molecular Biology. Additionally, they have two certifications: an Associate Fellow of Higher Education Academy from the Higher Education Academy, obtained in 2021, and a PIL - Personal License for Animal sperimentation Home Office - UK, obtained in 2008.